However, there have been isolated case reports of birth defects following foetal exposure to haloperidol, mostly in combination with other medicinal products. The central dopamine blocking effect has activity on the basal ganglia (nigrostriatal bundles).

In severe cases as many as 25 tablets or teaspoonfuls a day may be required, while in mild cases one to six tablets or teaspoonfuls a day may suffice.One to three 180 mg tablets, once or twice daily, will usually be sufficient to control symptoms; however, the needs of certain individuals may vary markedly from this average. Symptoms in women include: Mental illness is caused by heredity, biology, psychological trauma and environmental stressors.Psychotic disorders are a group of serious illnesses that affect the mind. The average dose is ten 60 mg tablets or ten 5 mL teaspoonfuls daily, spaced to provide maximum relief when maximum strength is needed. changes in menstruation and infertility,

Whilst on therapy, it is recommended to reduce the dose if QTc is prolonged, but haloperidol must be discontinued if the QTc exceeds 500 ms.Electrolyte disturbances such as hypokalaemia and hypomagnesaemia increase the risk for ventricular arrhythmias and must be corrected before treatment with haloperidol is started. • Certain medicinal products used in cancer (e.g. • Treatment of persistent aggression and psychotic symptoms in patients with moderate to severe Alzheimer's dementia and vascular dementia when non-pharmacological treatments have failed and when there is a risk of harm to self or others – 0.5 mg/day. Continue typing to refine. Data are not available for children aged less than 3 years.Haloperidol Oral Solution BP 10 mg/5 ml is for oral use. • Certain antibiotics (e.g.

• Certain other medicinal products (e.g. The cytochrome P450 enzymes CYP3A4 and CYP2D6 are involved in haloperidol metabolism. Animal studies have shown reproductive toxicity (see section 5.3).

Since haloperidol is extensively metabolised in the liver, it is recommended to halve the initial dose, and adjust the dose with smaller increments and at longer intervals than in patients without hepatic impairment (see sections 4.4 and 5.2).The dose recommendations for Haloperidol Oral Solution BP 10 mg/5 ml are presented in Table 4. • Combined CYP3A4 and CYP2D6 inhibitors: fluoxetine, ritonavir.Increased haloperidol plasma concentrations may result in an increased risk of adverse events, including QTcprolongation (see section 4.4). Haloperidol may antagonise the action of adrenaline and other sympathomimetic medicinal products (e.g.

Hiccups do not appear to perform any useful or protective function. •Doses above 10 mg/day have not demonstrated superior efficacy to lower doses in the majority of patients and may cause an increased incidence of extrapyramidal symptoms. It is recommended that patients be advised not to drive or operate machines during treatment, until their susceptibility is known.The safety of Haloperidol was evaluated in 284 haloperidol-treated subjects who participated in 3 placebo-controlled clinical studies and in 1295 haloperidol-treated patients who participated in sixteen double blind active comparator-controlled clinical studies. Persistent or protracted hiccups are rare and last more than 48 hours. • Haloperidol oral solution 2mg/mL .

Limited long-term safety data are available.Interaction studies have only been performed in adults.Haloperidol is contraindicated in combination with medicinal products known to prolong the QTc interval (see section 4.3). • Treatment of mild to moderate chorea in Huntington's disease, when other medicinal products are ineffective or not tolerated. This increase may be higher with all butyrophenones, including haloperidol. It is a potent central dopamine type 2 receptor antagonist, and at recommended doses, has low alpha-1 antiadrenergic activity and no antihistaminergic or anticholinergic activity.Haloperidol suppresses delusions and hallucinations as a direct consequence of blocking dopaminergic signalling in the mesolimbic pathway. It is more easily swallowed, especially in the morning, by patients with bulbar involvement.each containing 180 mg pyridostigmine bromide. Acute dystonia may necessitate stopping the medicinal product.Antiparkinson medicinal products of the anticholinergic type may be prescribed as required to manage extrapyramidal symptoms, but it is recommended that they are not prescribed routinely as a preventive measure. • All other indications – half the lowest adult dose.The haloperidol dose may be adjusted according to the patient's response.